0 8 Function function NN 9 12 and and CC 13 23 activation activation NN 24 26 of of IN 27 35 NF-kappa NF-kappa NNP 36 37 B B NNP 38 40 in in IN 41 44 the the DT 45 51 immune immune JJ 52 58 system system NN 58 59 . . . 61 69 NF-kappa NF-kappa NNP 70 71 B B NNP 72 74 is be VBZ 75 76 a a DT 77 87 ubiquitous ubiquitous JJ 88 101 transcription transcription NN 102 108 factor factor NN 108 109 . . . 110 122 Nevertheless nevertheless RB 122 123 , , , 124 127 its its PRP$ 128 138 properties property NNS 139 143 seem seem VBP 144 146 to to TO 147 149 be be VB 150 154 most most RBS 155 166 extensively extensively RB 167 176 exploited exploit VBN 177 179 in in IN 180 185 cells cell NNS 186 188 of of IN 189 192 the the DT 193 199 immune immune JJ 200 206 system system NN 206 207 . . . 208 213 Among among IN 214 219 these these DT 220 230 properties property NNS 231 234 are be VBP 235 243 NF-kappa NF-kappa NNP 244 245 B B NNP 245 247 ’s 's POS 248 253 rapid rapid JJ 254 271 posttranslational posttranslational JJ 272 282 activation activation NN 283 285 in in IN 286 294 response response NN 295 297 to to TO 298 302 many many JJ 303 313 pathogenic pathogenic JJ 314 321 signals signal NNS 321 322 , , , 323 326 its its PRP$ 327 333 direct direct JJ 334 347 participation participation NN 348 350 in in IN 351 370 cytoplasmic/nuclear cytoplasmic/nuclear JJ 371 380 signaling signaling NN 380 381 , , , 382 385 and and CC 386 389 its its PRP$ 390 397 potency potency NN 398 400 to to TO 401 409 activate activate VB 410 423 transcription transcription NN 424 426 of of IN 427 428 a a DT 429 434 great great JJ 435 442 variety variety NN 443 445 of of IN 446 451 genes gene NNS 452 460 encoding encode VBG 461 476 immunologically immunologically RB 477 485 relevant relevant JJ 486 494 proteins protein NNS 494 495 . . . 496 498 In in IN 499 510 vertebrates vertebrate NNS 510 511 , , , 512 516 five five CD 517 525 distinct distinct JJ 526 529 DNA dna NN 530 537 binding binding NN 538 546 subunits subunit NNS 547 550 are be VBP 551 560 currently currently RB 561 566 known know VBN 567 572 which which WDT 573 578 might might MD 579 590 extensively extensively RB 591 605 heterodimerize heterodimerize VB 605 606 , , , 607 614 thereby thereby RB 615 622 forming form VBG 623 632 complexes complex NNS 633 637 with with IN 638 646 distinct distinct JJ 647 662 transcriptional transcriptional JJ 663 671 activity activity NN 671 672 , , , 673 676 DNA DNA NNP 677 685 sequence sequence NN 686 697 specificity specificity NN 697 698 , , , 699 702 and and CC 703 707 cell cell NN 708 713 type- type- NN 714 717 and and CC 718 722 cell cell NN 723 737 stage-specific stage-specific JJ 738 750 distribution distribution NN 750 751 . . . 752 755 The the DT 756 764 activity activity NN 765 767 of of IN 768 771 DNA DNA NNP 772 779 binding binding NN 780 788 NF-kappa NF-kappa NNP 789 790 B B NNP 791 797 dimers dimer NNS 798 800 is be VBZ 801 808 tightly tightly RB 809 819 controlled control VBN 820 822 by by IN 823 832 accessory accessory JJ 833 841 proteins protein NNS 842 848 called call VBN 849 850 I i NN 851 856 kappa kappa NN 857 858 B B NNP 859 867 subunits subunit NNS 868 870 of of IN 871 876 which which WDT 877 882 there there EX 883 886 are be VBP 887 891 also also RB 892 896 five five CD 897 906 different different JJ 907 914 species specie NNS 915 924 currently currently RB 925 930 known know VBN 931 933 in in IN 934 945 vertebrates vertebrate NNS 945 946 . . . 947 948 I i NN 949 954 kappa kappa NN 955 956 B B NNP 957 965 proteins protein NNS 966 973 inhibit inhibit VBP 974 977 DNA DNA NNP 978 985 binding binding NN 986 989 and and CC 990 997 prevent prevent VB 998 1005 nuclear nuclear JJ 1006 1012 uptake uptake NN 1013 1015 of of IN 1016 1024 NF-kappa NF-kappa NNP 1025 1026 B B NNP 1027 1036 complexes complex NNS 1036 1037 . . . 1038 1040 An an DT 1041 1050 exception exception NN 1051 1053 is be VBZ 1054 1057 the the DT 1058 1063 Bcl-3 bcl-3 NN 1064 1071 protein protein NN 1072 1077 which which WDT 1078 1080 in in IN 1081 1089 addition addition NN 1090 1093 can can MD 1094 1102 function function VB 1103 1105 as as IN 1106 1107 a a DT 1108 1121 transcription transcription NN 1122 1132 activating activating NN 1133 1140 subunit subunit NN 1141 1143 in in IN 1144 1146 th th JJ 1147 1154 nucleus nucleus NN 1154 1155 . . . 1156 1161 Other other JJ 1162 1163 I i NN 1164 1169 kappa kappa NN 1170 1171 B B NNP 1172 1180 proteins protein NNS 1181 1184 are be VBP 1185 1191 rather rather RB 1192 1200 involved involve VBN 1201 1203 in in IN 1204 1215 terminating terminate VBG 1216 1224 NF-kappa NF-kappa NNP 1225 1226 B B NNP 1226 1228 ’s 's POS 1229 1237 activity activity NN 1238 1240 in in IN 1241 1244 the the DT 1245 1252 nucleus nucleus NN 1252 1253 . . . 1254 1257 The the DT 1258 1271 intracellular intracellular JJ 1272 1278 events event NNS 1279 1283 that that WDT 1284 1288 lead lead VBP 1289 1291 to to TO 1292 1295 the the DT 1296 1308 inactivation inactivation NN 1309 1311 of of IN 1312 1313 I i NN 1314 1319 kappa kappa NN 1320 1321 B B NNP 1321 1322 , , , 1323 1327 i.e. i.e. FW 1328 1331 the the DT 1332 1342 activation activation NN 1343 1345 of of IN 1346 1354 NF-kappa NF-kappa NNP 1355 1356 B B NNP 1356 1357 , , , 1358 1361 are be VBP 1362 1369 complex complex JJ 1369 1370 . . . 1371 1375 They they PRP 1376 1383 involve involve VBP 1384 1399 phosphorylation phosphorylation NN 1400 1403 and and CC 1404 1415 proteolytic proteolytic JJ 1416 1425 reactions reaction NNS 1426 1429 and and CC 1430 1434 seem seem VBP 1435 1437 to to TO 1438 1440 be be VB 1441 1451 controlled control VBN 1452 1454 by by IN 1455 1458 the the DT 1459 1464 cells cell NNS 1464 1465 ’ ' POS 1466 1471 redox redox NN 1472 1478 status status NN 1478 1479 . . . 1480 1492 Interference interference NN 1493 1497 with with IN 1498 1501 the the DT 1502 1512 activation activation NN 1513 1515 or or CC 1516 1524 activity activity NN 1525 1527 of of IN 1528 1536 NF-kappa NF-kappa NNP 1537 1538 B B NNP 1539 1542 may may MD 1543 1545 be be VB 1546 1556 beneficial beneficial JJ 1557 1559 in in IN 1560 1571 suppressing suppress VBG 1572 1584 toxic/septic toxic/septic JJ 1585 1590 shock shock NN 1590 1591 , , , 1592 1605 graft-vs-host graft-vs-host JJ 1606 1615 reactions reaction NNS 1615 1616 , , , 1617 1622 acute acute JJ 1623 1635 inflammatory inflammatory JJ 1636 1645 reactions reaction NNS 1645 1646 , , , 1647 1652 acute acute JJ 1653 1658 phase phase NN 1659 1667 response response NN 1667 1668 , , , 1669 1672 and and CC 1673 1682 radiation radiation NN 1683 1689 damage damage NN 1689 1690 . . . 1691 1694 The the DT 1695 1705 inhibition inhibition NN 1706 1708 of of IN 1709 1717 NF-kappa NF-kappa NNP 1718 1719 B B NNP 1720 1730 activation activation NN 1731 1733 by by IN 1734 1746 antioxidants antioxidant NNS 1747 1750 and and CC 1751 1759 specific specific JJ 1760 1768 protease protease NN 1769 1779 inhibitors inhibitor NNS 1780 1783 may may MD 1784 1791 provide provide VB 1792 1793 a a DT 1794 1809 pharmacological pharmacological JJ 1810 1815 basis basis NN 1816 1819 for for IN 1820 1831 interfering interfere VBG 1832 1836 with with IN 1837 1842 these these DT 1843 1848 acute acute JJ 1849 1858 processes process NNS 1858 1859 . . .